ClinicalTrials.gg
Active, not recruitingNCT06991556Updated Nov 13, 2026

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

A Phase 2 interventional study of JSB462 and Abiraterone in Metastatic Hormone-sensitive Prostate Cancer, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 64 sites in 15 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Updated Nov 13, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Prostatic Neoplasms by Novartis — 13 open to participants now, 26 under way, 4 of them phase 3. Prostatic Neoplasms · Novartis.

Enrollment
23rd of 70
168 · median 72
Started
2025
with 10 others
Phase 2
16 of 82
none open now
Primary completion
2026-12
later than 5 of 25 live
Registered
69th of 82
by date

Among the 82 studies in Prostatic Neoplasms by Novartis, this one is the 23rd largest by enrollment of the 70 interventional ones that give a count, is one of 11 that started in 2025, is one of 16 in phase 2, reaches primary completion later than 5 of the 25 other live ones, and was the 69th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

13 of the 82 studies in Prostatic Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Prostatic Neoplasms by Novartis, or all of them as a file.
02

Study summary

This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated

Read the detailed description

The study for each participant consists of a Screening period (28 days), a treatment period, a post-treatment safety follow-up (30 days) followed by a long-term follow-up period.

During the treatment period:

  • JSB462 is administered from randomization, orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
  • Abiraterone 1000 mg or enzalutamide 160 mg are administered from randomization, orally, daily, and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.

During the post-treatment follow up period:

  • Safety follow-Up: After discontinuation of study treatment, all participants will be followed for at least 1 safety follow-up visit (30 days [+/- 7 days] after treatment discontinuation). Subsequent lines of therapy may be administered according to investigator's discretion after treatment discontinuation.
  • Long-term follow-up: Starts after the Safety follow-up period and lasts until the end of study. Safety, efficacy and survival information may be collected from participants during this period.
03

Conditions studied

  • Metastatic Hormone-sensitive Prostate Cancer

Browse trials for

Keywords

  • Interventional
  • clinical trial
  • open-label
  • JSB462
  • luxdegalutamide
  • efficacy
  • safety
  • tolerability
  • abiraterone
  • metastatic hormone-sensitive prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • An (ECOG) Performance Status (PS) ≤2
  • confirmed adenocarcinoma of the prostate. Participants with mixed histology (neuroendocrine) are not eligible
  • High-volume mHSPC, defined by the presence of ≥1 visceral non-nodal lesion and/or ≥4 metastatic bone lesions (with at least one lesion outside the vertebral column and/or pelvis) in imaging exams (CT/MRI or bone scan) according to local radiology assessment by the investigator obtained ≤28 days prior to randomization
  • Participants must have a castrate level of serum/plasma testosterone (\<50 ng/dL or \<1.7 nmol/L). Ongoing ADT (as defined by prior orchiectomy and/or ongoing GnRH analog/antagonist) for ≤90 days is allowed prior to randomization, provided that PSA zero (PSA level \<0.2 ng/ml according to local laboratory as assessed by the investigator) is not achieved prior to randomization.

Key Exclusion Criteria:

  • Prior exposure to a second generation ARPI (such as enzalutamide/darolutamide/apalutamide and/or abiraterone) for the treatment of advanced/metastatic disease is not allowed. Prior exposure to ARPI, to taxane chemotherapy (up to 6 cycles) or to RLT in the context of (neo) treatment for localized prostate cancer is allowed, if the last dose of this treatment was administered >12 months from randomization. Prior use of a first generation ARPI (such as bicalutamide) in the context of ADT initiation with a GnRH analog is allowed, provided the first generation ARPI was administered for ≤14 days and last dose was administered ≥7 days from randomization.
  • Participants with biochemical recurrence only or those without evidence of metastatic disease by radiological imaging (CT/MRI or bone scan) are not eligible

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Arm 1

    JSB462 100 mg QD + abiraterone 1000 mg QD

    Drug: JSB462 · Drug: Abiraterone

  • Experimental
    Arm 2

    JSB462 300 mg QD + abiraterone 1000 mg QD

    Drug: JSB462 · Drug: Abiraterone

  • Active comparator
    Arm 3

    abiraterone 1000 mg QD or enzalutamide 160 mg QD

    Drug: Abiraterone · Drug: Enzalutamide

Interventions

  • DrugJSB462

    JSB462 is administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.

    Also known as: luxdegalutamide

  • Abiraterone 1000 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.

  • Enzalutamide 160 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.

06

What researchers measure

Primary outcomes

  1. Prostate Specific Antigen 90 (PSA90) Rate

    Prostate Specific Antigen 90 (PSA90) Rate is defined as the proportion of participants who achieve a ≥90% decrease in PSA from baseline at any timepoint, confirmed by a second PSA measurement ≥3 weeks without any PSA progression in between.

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  2. Incidence rate of adverse events (AEs)

    The analysis of adverse events will include categorization by type, frequency, and severity, as graded by the NCI CTCAE version 5.0.

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  3. Number of participants with dose adjustments

    The number of participants with dose adjustments (reductions, interruption, or permanent discontinuation) will be summarized by treatment arm.

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  4. Duration of exposure to study treatment

    The duration of exposure in weeks to study treatment and for each study treatment component (JSB462, abiraterone and enzalutamide) will be summarized for each study treatment component by means of descriptive statistics using the SAS.

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

Secondary outcomes

  1. Radiographic Progression Free Survival (rPFS)

    Radiographic Progression Free Survival (rPFS) is defined as the time between randomization and the first occurrence of disease progression (per PCWG3-modified RECIST 1.1 as assessed by the investigator) or death due to any cause

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 83 months

  2. Overall Survival (OS)

    Overall Survival (OS) is defined as the time between randomization and death due to any cause

    Time frame: From date of randomization until date of death from any cause, assessed up to approximately 83 months

  3. Incidence rate of adverse events (AEs)

    The analysis of adverse events and laboratory abnormalities will include categorization by type, frequency, and severity, as graded by the NCI CTCAE version 5.0.

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 83 months

  4. Overall Response Rate (ORR)

    Overall Response Rate (ORR) is defined as the proportion of participants achieving a confirmed complete response (CR) or partial response (PR) per PCWG3-modified RECIST 1.1 as assessed by the investigator

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 83 months

  5. Disease Control Rate (DCR)

    Disease Control Rate (DCR) is defined as the proportion of participants achieving a CR, PR or stable disease (SD) per PCWG3-modified RECIST 1.1 as assessed by the investigator

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 83 months

  6. Duration of Response (DOR)

    Duration of Response (DOR) is defined as the time between first documented CR/PR and disease progression or death due to any cause per PCWG3-modified RECIST 1.1 as assessed by the investigator

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 83 months

  7. Time to Response (TTR)

    Time to response (TTR) is defined as the time from randomization to the date of first documented CR or PR per PCWG3-modified RECIST 1.1 as assessed by the investigator

    Time frame: From date of randomization until date of first documented Complete Response (CR) or Partial Response (PR), assessed up to approximately 83 months

  8. Time to soft tissue progression (TTSTP)

    Time to soft tissue progression (TTSTP) is defined as the time from randomization to the date of first documented radiographic soft tissue progression per PCWG3-modified RECIST 1.1 as assessed by the investigator

    Time frame: From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 83 months

  9. Prostate Specific Antigen 30 (PSA30) Rate

    Prostate Specific Antigen 30 (PSA30) Rate is defined as the proportion of participants who achieve a ≥30% decrease from baseline at any timepoint, confirmed by a second PSA measurement ≥3 weeks without any PSA progression in between

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  10. Prostate Specific Antigen 50 (PSA50) Rate

    Prostate Specific Antigen 50 (PSA50) Rate is defined as the proportion of participants who achieve a ≥50% decrease from baseline at any timepoint, confirmed by a second PSA measurement ≥3 weeks without any PSA progression in between

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  11. Prostate Specific Antigen 0 (PSA0) Rate

    Prostate Specific Antigen 0 (PSA0) Rate is defined as the proportion of participants who achieve a PSA level \<0.2 ng/ml at any timepoint after start of treatment, confirmed by a second PSA measurement ≥3 weeks without any PSA progression in between

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  12. Duration of biochemical response (DBR)

    Duration of biochemical response (DBR) is defined as the time between PSA90 and/or PSA0 and PSA progression (increase ≥25% in PSA and an absolute increase of ≥2 ng/mL from NADIR) or death due to any cause

    Time frame: From date of date of first PSA50 response until date of PSA progression or death from any cause, assessed up to approximately 83 months

  13. Time to first symptomatic skeletal event (TTSSE)

    Time to first symptomatic skeletal event (TTSSE) is defined as the date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first

    Time frame: From date of randomization till EOT or death, whichever happens first, assessed up to approximately 83 months

  14. Plasma concentrations of JSB462 and plasma concentrations of its metabolite ARV-767

    JSB462 pharmacokinetic (PK) samples will be obtained and evaluated in all participants at all dose levels in JSB462 treatment arms.

    Time frame: Day 1 of Cycles 1 and 2: Pre-dose/0h and Post-dose 4h +/- 1h. Day 1 of Cycles 3 to 8: Pre-dose/0h. End of Treatment Visit (EOT): Anytime. 1 cycle = 28 days.

  15. Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    The PRO-CTCAE is a patient-reported outcomes measurement system developed by the National Cancer Institute as a companion to the CTCAE. It includes items covering participant-reported symptomatic adverse events (AEs) from the CTCAE. Each symptomatic AE concept has up to three items evaluating frequency, severity, or interference, focused on the study population and treatment regimens. Participants respond on a 5-point scale for each item: * Frequency: Never, Rarely, Occasionally, Frequently, Almost constantly * Severity: None, Mild, Moderate, Severe, Very severe * Interference: Not at all, A little bit, Somewhat, Quite a bit, Very much The past 7-day recall version is used, focusing on relevant symptoms like fatigue, diarrhea, and hot flashes.

    Time frame: From randomization up till 30 day safety Follow-up, assessed up to approximately 83 months

07

Study locations

64 sites
  • University of California San Diego - Moores Cancer Center
    La Jolla, California 92093-0658, United States
  • Saint Johns Cancer Institute
    Santa Monica, California 90404, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • Advanced Urology Ins Daytona Beach
    Daytona Beach, Florida 32114, United States
  • Emory University School of Medicine-Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Associated Urological Specialists
    Chicago Ridge, Illinois 60415, United States
  • Mass General Hospital
    Boston, Massachusetts 02114, United States
  • Michigan Institute of Urology
    West Bloomfield, Michigan 48322, United States
  • XCancer Omaha LLC
    Omaha, Nebraska 68130, United States
  • Perlmutter Cancer Centre
    New York, New York 10016, United States
  • Associated Med Professionals of NY
    Syracuse, New York 13210, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • MidLantic Urology
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Urology San Antonio
    San Antonio, Texas 78229, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Fred Hutch Cancer Research
    Seattle, Washington 98109, United States
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    Fortaleza, Ceará 60140-025, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01221-020, Brazil
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H4A 3J1, Canada
  • Novartis Investigative Site
    Beijing, Chaoyang 100021, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Brno, 656 53, Czechia
  • Novartis Investigative Site
    Olomouc, 779 00, Czechia
  • Novartis Investigative Site
    Prague, 150 06, Czechia
  • Novartis Investigative Site
    Nice, Alpes Maritimes 06189, France
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Quint-Fonsegrives, 31130, France
  • Novartis Investigative Site
    Suresnes, 92150, France
  • Novartis Investigative Site
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Lübeck, 23538, Germany
  • Novartis Investigative Site
    Nürtingen, 72622, Germany
  • Novartis Investigative Site
    Asti, AT 14100, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Trento, TN 38122, Italy
  • Novartis Investigative Site
    Orbassano, TO 10043, Italy
  • Novartis Investigative Site
    Verona, VR 37134, Italy
  • Novartis Investigative Site
    Zwolle, Overijssel 8025 AB, Netherlands
  • Novartis Investigative Site
    Hoofddorp, 2134 TM, Netherlands
  • Novartis Investigative Site
    Kielce, 25-640, Poland
  • Novartis Investigative Site
    Oświęcim, 32-600, Poland
  • Novartis Investigative Site
    Skorzewo, 60-185, Poland
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Singapore, 308433, Singapore
  • Novartis Investigative Site
    Seoul, 03080, South Korea
  • Novartis Investigative Site
    Seoul, 06351, South Korea
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Badajoz, Extremadura 06080, Spain
  • Novartis Investigative Site
    Lugo, Galicia 27003, Spain
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Kaohsiung City, 833, Taiwan
  • Novartis Investigative Site
    Tainan, 704302, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 16 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

Primary completion moved twice since we started tracking on Sep 25, 2026: Feb 2032 → Dec 2026, last on Nov 10, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Sep 2035 → Oct 2035, last on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 28, 2025
StartActual
Jul 7, 2025
Primary completionEst.
Dec 3, 2026was Feb 2032
CompletionEst.
Oct 18, 2035was Sep 2035
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 3 sites removed
Show site
  • Novartis Investigative Site · Schiedam, Netherlands
Show 3 removed
  • Novartis Investigative Site · Schiedam, Netherlands
  • Novartis Investigative Site · Dordrecht, Netherlands
  • Novartis Investigative Site · Schiedam, Netherlands
across 3 updates, Oct 14, 2026 – Nov 13, 2026
Primary completion
Feb 13, 2032→Dec 3, 2026
moved 2 times, Oct 9, 2026 – Nov 10, 2026
Study completion
Sep 4, 2035→Oct 18, 2035
moved 2 times, Oct 9, 2026 – Nov 10, 2026
Show all 4 updates
  1. Nov 13, 2026
    2 sites removed
    Show 2 removed
    • Novartis Investigative Site · Dordrecht, Netherlands
    • Novartis Investigative Site · Schiedam, Netherlands
  2. Nov 10, 2026
    1 site added
    Show site
    • Novartis Investigative Site · Schiedam, Netherlands
    Primary completion Mar 15, 2032→Dec 3, 2026
    Study completion Oct 4, 2035→Oct 18, 2035
    + 1 other change: verification date
  3. Oct 14, 2026
    1 site removed
    Show 1 removed
    • Novartis Investigative Site · Schiedam, Netherlands
  4. Oct 9, 2026
    Primary completion Feb 13, 2032→Mar 15, 2032
    Study completion Sep 4, 2035→Oct 4, 2035
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06991556
Responsible party
Sponsor
First posted
May 28, 2025
Start date
Jul 7, 2025
Primary completion
Dec 3, 2026 (estimated)
Completion
Oct 18, 2035 (estimated)
Last update
Nov 13, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JSB462

Start the discussion